{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["copanlisib","rucaparib"]],"indication":"metastatic castration-resistant prostate cancer","name":"BrUOG360","nct_id":"NCT04253262","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bruog360-nct04253262. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"300 mg Rucaparib, 45 mg (day 1 \\& 15) Copanlisib","label":"Dose Level -2","type":"EXPERIMENTAL"},{"description":"400 mg Rucaparib, 45 mg (day 1 \\& 15) Copanlisib","label":"Dose Level -1","type":"EXPERIMENTAL"},{"description":"400 mg Rucaparib, 45 mg Copanlisib","label":"Dose Level 1","type":"EXPERIMENTAL"},{"description":"500 mg Rucaparib, 45 mg Copanlisib","label":"Dose Level 2","type":"EXPERIMENTAL"},{"description":"600 mg Rucaparib, 45 mg Copanlisib","label":"Dose Level 3","type":"EXPERIMENTAL"},{"description":"600 mg Rucaparib, 60 mg Copanlisib","label":"Dose Level 4","type":"EXPERIMENTAL"}],"collaborators":["Rhode Island Hospital","The Miriam Hospital","Bayer","Clovis Oncology, Inc."],"completion_date":{"date":"2027-01","type":"ESTIMATED"},"conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":{"count":13,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Rucaparib","otherNames":["Rubraca"],"type":"DRUG"},{"name":"Copanlisib","otherNames":["Aliqopa"],"type":"DRUG"}],"last_update":"2025-05-04","lead_sponsor":"Brown University","official_title":"A Phase Ib/II Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Maximum Tolerated Dose","timeFrame":"Cycle 1 (each cycle is 28 days) through pre-dosing cycle 2, approximately 1 month."},{"measure":"Response","timeFrame":"Every 28 days on treatment, then every 3 months until progression of disease up to 3 years."}],"references":[],"start_date":{"date":"2020-04-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04253262"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bruog360-nct04253262"}